Theranostic niosomes as a promising tool for combined therapy and diagnosis: "all-in-one" approach

Basit Öğe Kaydı
dc.contributor.authorDemir B.
dc.contributor.authorBarlas F.B.
dc.contributor.authorGumus Z.P.
dc.contributor.authorUnak P.
dc.contributor.authorTimur S.
dc.date.accessioned2021-05-03T20:48:02Z
dc.date.available2021-05-03T20:48:02Z
dc.date.issued2018
dc.description.abstractBecause of the great achievement and progress made for the generation of novel nanostructures, theranostic nanoplatforms have been the trending topic because of their intensive capability of therapy and diagnosis. Hence, theranostics have also recently been a generic strategy for personalized medicine. Moreover, traditional therapy modalities limit the use of chemotherapeutic agents for every patient, and this requires more effective drug-carrier systems by designing the formulation of drug in a specified way. Herein, we performed a generic theranostic platform in an "all-in-one" concept by the combination of two therapy modalities with an active targeting approach. To achieve this, 10 nm gold nanoparticles (AuNPs) and protoporphyrin IX (PpIX) were encapsulated into folic acid (FA-)tagged niosome vesicles. The resulting AuNP-PpIX-FA niosomes were characterized, and their particle size was93 ± 17 nm with a high surface charge and encapsulation efficiency (around 85%). In the case of bioapplications for AuNP-PpIX-FA niosomes, folate-receptor-positive [FR(+)] human cervical cancer (HeLa) and FR-negative [FR(-)] human alveolar type II (A549)-like cell lines were examined with the relative control groups of theranostic vesicles. By testing the toxicity of vesicles, nontoxic concentrations were successfully introduced to the cell with the combined treatment of radiotherapy and photodynamic therapy. On the other hand, the cellular uptake of niosomes also showed great potential for FR(+) HeLa cells as the theranostic platform with an all-in-one approach. Copyright © 2018 American Chemical Society.en_US
dc.identifier.doi10.1021/acsanm.8b00468
dc.identifier.endpage2835en_US
dc.identifier.issn2574-0970
dc.identifier.issn2574-0970en_US
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85055930824en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2827en_US
dc.identifier.urihttps://doi.org/10.1021/acsanm.8b00468
dc.identifier.urihttps://hdl.handle.net/11454/70704
dc.identifier.volume1en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.relation.ispartofACS Applied Nano Materialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcell imagingen_US
dc.subjectmultimodal nanoparticlesen_US
dc.subjectniosomesen_US
dc.subjecttargeted therapyen_US
dc.subjecttheranosticsen_US
dc.titleTheranostic niosomes as a promising tool for combined therapy and diagnosis: "all-in-one" approachen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu